Montclair State University

PDE5 inhibitors stop the degradation of cGMP-specific phosphodiesterase type 5 (PDE5), thereby enhancing the vasodilatory effects of nitric oxide. PDE5 inhibitors have been shown to have a favorable effect on increasing exercise capacity and decreasing PAP in PAH clinical studies. ................
................